BioXcel Therapeutics, Inc.·4/A

Sep 17, 7:17 PM ET

Wiley Matthew T. 4/A

4/A · BioXcel Therapeutics, Inc. · Filed Sep 17, 2024

Insider Transaction Report

Form 4/AAmended
Period: 2024-06-15
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2024-06-157508,250 total
    Common Stock (750 underlying)
Footnotes (2)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  • [F2]On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Documents

1 file
  • 4
    tm2424255-4_4aseq1.xml

    OWNERSHIP DOCUMENT